Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma

  title={Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma},
  author={Bao-jin Wu and Wen-peng Li and Cheng Qian and Wei Ding and Zhong-wen Zhou and Hua Jiang},
  journal={Tumor Biology},
Thymidine kinase 1 (TK1) is involved in cancer progression. Metastatic site is a prognostic factor in melanoma. We assessed whether serum levels of TK1 are associated with metastatic sites or prognosis in patients treated for stage IV melanoma. The study included 64 patients, who received dacarbazine or four-drug chemotherapy (dacarbazine, vincristine, bleomycin, and lomustine) both combined with interferon-alfa. Serum samples for TK1 were analyzed by ELISA. The patients (n = 22) with only skin… 

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

Results suggest that TK1 activity measured by DiviTum™ predicted therapy response, PFS and OS in loco regional inoperable or disseminated breast cancer, and this factor is a useful serum marker.

Thymidine Kinase 1: A Universal Marker for Cancer

TK1 is a good marker for malignancy and is significantly overexpressed in cancers compared to normal controls in lung, colon, prostate, esophagus, stomach, liver, and kidney tissues and may be considered a universal cancer marker.

Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies

TK1 localizes on the surface of lung, breast, and colorectal cell lines and is upregulated in malignant tissue and patients compared to healthy tissues and patients, concluding that TK1 is a potential clinical biomarker for the treatment of lung and breast cancer.

A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease

The first clinical results with the newly developed TK 210 ELISA from AroCell AB strongly suggests that it can provide independent and complementary information for patients with breast cancer.

The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma

The detection of serum thymidine kinase 1 might have high clinical value in auxiliary diagnosis, curative effect monitoring, and prognosis judgment of colorectal carcinoma.

Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival

The study shows that expression of the molecular marker Mitf in primary cutaneous melanomas is a useful tool in assessing lymph node status, and Mitf immunostaining in the primary tumor serves as a reliable predictor of occult lymph node metastases, as well as a favorable prognosticator of DFS and OS in melanoma patients.

TK1 overexpression is associated with the poor outcomes of lung cancer patients: a systematic review and meta-analysis.

The TK1 expression might have a supportive implication in assessing biological behavior and prognosis of lung cancer patients and be associated with poorer overall survival in patients with lung cancer.

Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells

The targeting of TK1 in malignant cells using monoclonal antibodies may be a feasible approach for the elimination of high Tk1 expressing tumor cells.

Biomarker Analysis and Clinical Relevance of Thymidine Kinase 1 in Solid and Hematological Malignancies

This dissertation described the characterization of TK1 as a cancer biomarker that associates with the plasma membrane of hematological malignancies such as Burkitt’s lymphoma, acute lymphoblastic leukemia, acute promyelocyticukemia, acute T cell lymphomas, and solid malignancy such as lung, breast, and colon cancer.

Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt’s lymphoma and acute lymphoblastic leukemia

TK1 is upregulated and localizes on the plasma membrane of Burkitt’s lymphoma, acute promyelocytic leukemia, T cell leukemia, and acute lymphoblastic leukemia (ALL) and exhibits enzymatic activity, which suggests TK1 as a possible target for immunotherapy with the potential to be utilized in the treatment of hematological cancers.



Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.

It is suggested that serum TK1 levels correlate with clinical stage, ECOG PS and serum CEA levels in patients with gastric cancer, and changes in STK1 Levels during the first 2 months of chemotherapy may be more important for evaluating chemotherapy response, predicting PFS and RFS than baseline values of STK2.

Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.

The serum TK level in CLL patients provides useful prognostic information regarding both response to therapy and length of survival and should be used in planning appropriate therapy.

Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.

Since STK1 concentration correlates with tumor stage, degree of invasion and metastasis, and monitors the surgical outcome, it can be a reliable index to diagnose and determine prognosis in post-operative bladder carcinoma.

Clinical Value of Thymidine Kinase in Patients with Cervical Carcinoma

TK may play an important role in influencing the malignant behavior of cervical carcinoma, and measurement of the serum TK level may be useful in predicting survival in patients with cervical carcinomas.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

BACKGROUND Gene expression profiling data for human primary cutaneous melanomas are scarce because of the lack of retrospective collections of frozen tumors. To identify differentially expressed

Enzymes as prognostic markers and therapeutic indicators in patients with cancer.

  • M. Schwartz
  • Medicine, Biology
    Clinica chimica acta; international journal of clinical chemistry
  • 1992

Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.

  • B. Madewell
  • Medicine, Biology
    Journal of veterinary internal medicine
  • 2004
Thymidine kinase seems to be a useful marker in non-Hodgkin's lymphoma, where it correlates with clinical staging and provides marked prognostic information on (progression-free) survival.

Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

A systematic review and meta-analysis of the published literature that reported immunohistochemistry-based protein biomarkers of melanoma outcome found promising markers that emerged and noted incomplete adherence to the REMARK guidelines.

Thin Melanomas: Predictive Lethal Characteristics From a 30-Year Clinical Experience

Thin melanomas are potentially lethal lesions and traditionally accepted negative prognostic factors such as ulceration and discordant Clark levels are not predictive for metastasis in this population of patients.

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  • C. BalchA. Buzaid J. Thompson
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
This revision of the staging system for cutaneous melanoma will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.